Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Summary not available.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the Bank of America Securities 2023 Health Care Conference. This event is set for May 9, 2023, at 10:00 a.m. (PT), held at the Encore Hotel in Las Vegas, Nevada. Attendees can access a live audio webcast of the presentation on the Teleflex investor website.
Teleflex specializes in medical technologies aimed at enhancing health and quality of life, offering solutions in vascular access, cardiology, anesthesia, and more. Their innovative approaches address critical clinical needs, benefiting patients and healthcare professionals alike.
Teleflex (NYSE: TFX) will host a conference call on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter financial results and operational updates. Participants can pre-register using the provided link to receive dial-in information. The call will be available via audio webcast on the Teleflex website, and a replay will be accessible after 11:00 a.m. ET on the same day. Teleflex is a global leader in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, anesthesia, and surgical solutions. For further information, stakeholders can visit Teleflex's official website.
Teleflex Incorporated (NYSE: TFX) has announced a supply agreement with W. L. Gore & Associates to integrate GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement into its Titan SGS® Powered Stapling Device for bariatric surgery. This partnership aims to enhance surgical outcomes by combining the advanced technology of the Titan device, specifically designed for sleeve gastrectomy, with Gore's proven staple line reinforcement material. The Titan SGS® offers significant advantages, including reducing stapling time by half and providing a consistent gastric sleeve anatomy. The collaboration highlights both companies' commitment to innovation in the bariatric surgery space.
Teleflex (NYSE: TFX) presented significant findings regarding the UroLift® System for treating benign prostatic hyperplasia (BPH) at the 38th Annual European Association of Urology Congress. Research from over 330 controlled subjects indicates that the UroLift® offers durable results at one and five years, with lower durability linked to undertreatment. Early intervention positively affects quality of life and sexual function. Notably, UroLift® demonstrated a lower complication rate compared to traditional surgeries like TURP. The studies reinforce UroLift® as a leading minimally invasive treatment for BPH, emphasizing its safety and effectiveness.
Teleflex is set to present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:00 p.m. (ET). Thomas Powell, the Executive Vice President and Chief Financial Officer, will deliver the presentation. A live audio webcast will be accessible on the Teleflex investor website. Teleflex, traded as TFX on NYSE, specializes in medical technologies aimed at enhancing health and quality of life, offering solutions across various fields including vascular access, anesthesia, and surgical care. For more details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2023. Shareholders of record as of March 3, 2023 will receive this dividend. Teleflex is dedicated to delivering innovative medical technologies aimed at enhancing healthcare quality and outcomes. Their product range spans multiple sectors, including vascular access, interventional cardiology, and anesthesia. This dividend declaration reflects the company's commitment to returning value to its shareholders while supporting ongoing business growth.
Teleflex Incorporated (NYSE: TFX) reported its Q4 2022 financial results, with revenues of $758.0 million, a slight decline of 0.5% year-over-year, but a 3.7% rise on a constant currency basis. GAAP diluted EPS decreased to $1.65 from $2.69 in Q4 2021. For full year 2022, revenues were $2,791.0 million, down 0.7%, with a GAAP diluted EPS of $7.67, compared to $10.23 in 2021. Looking ahead, Teleflex expects revenue growth of 4.25% to 5.75% for 2023, and GAAP EPS guidance of $8.26 to $8.86. The company emphasizes its commitment to durable growth amidst challenges.
Teleflex Incorporated (NYSE: TFX) announced significant advancements in interventional cardiology with the FDA 510(k) clearance of the Triumph™ Catheter and the first clinical use of the GuideLiner® Coast™ Catheter. The Triumph™ Catheter features six wire exit ports designed for better navigation in complex anatomy. Developed with Dr. Bill Nicholson, it aims to improve catheter navigation. The GuideLiner® Coast™ Catheter adds hydrophilic options to the existing portfolio. Both products will be showcased at the CTO Plus Conference on February 23-24 in New York, with full market release expected later in 2023.
Teleflex Incorporated (NYSE: TFX) will have its Chairman, President, and CEO, Liam Kelly, speaking at the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 1:40 p.m. (ET). The conference will take place at the JW Marriott Orlando Grande Lakes, Orlando, FL.
A live audio webcast and accompanying presentation slides will be available on the investor section of Teleflex's website for those unable to attend in person.
Teleflex specializes in innovative medical technologies that improve healthcare quality, offering solutions across various medical fields.